

## Press Release

### Syngene purchases land to expand operations in Genome Valley, Hyderabad

- The Ground-breaking ceremony was hosted by Kiran Mazumdar Shaw, Non-executive Chairperson, Syngene, and graced by K. T. Rama Rao, Hon'ble Minister of IT, Industries and Commerce, Telangana Government
- Syngene plans to build state-of-the-art research laboratories and create up to 1000 jobs

**Hyderabad, 14 September 2023: Syngene International Limited**, a leading global contract research, development, and manufacturing services organization, announced the purchase of a 17-acre land parcel in Genome Valley, Hyderabad as an extension to its existing research campus. Construction of the new facilities will begin in 2024, following the necessary statutory approvals. The Company anticipates an investment of up to INR 788 crores to develop the expanded campus in Genome Valley to its full potential, including the creation of up to 1000 jobs in science, in the next 5 years.

The ground-breaking ceremony was graced by Honorable Minister Mr. K.T Rama Rao, Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications, Government of Telangana, Kiran Mazumdar Shaw, Chairperson, Syngene International Limited, Mr. Jayesh Ranjan, IAS, Principle Secretary, Industries and Commerce and IT, Government of Telangana, Mr. Venkata Narsimha Reddy, IAS, Vice Chairman & Managing Director - Telangana State Industrial Infrastructure Corporation (TSIIC), Mr. Shakthi Nagappan, Chief Executive Officer, Telangana Life Sciences, Mahesh Bhalgat, Chief Operating Officer, Syngene International and other senior leaders from Syngene.

Syngene's existing research facility in Genome Valley was inaugurated in 2020 and accommodates over 900 scientists. The research carried out on the site focuses on discovery chemistry and biology, primarily for the global pharmaceutical industry. The site also includes a PROTAC laboratory that conducts leading edge research into disease-causing proteins, which lie at the heart of diseases such as cancer and a Central Compound Management facility which serves as a central storage facility for all compounds synthesized by Syngene scientists.

**K. T. Rama Rao, Honourable Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications, Government of Telangana** expressed *"Syngene's expansion is a testament to the tremendous opportunities and support that our state provides. At Genome Valley, we aim to facilitate the necessary infrastructure and support systems to enable pioneering lifescience R&D activities. This expansion aligns with our vision to attract and nurture top talent, drive innovation and foster economic development."*

**Kiran Mazumdar Shaw, Chairperson of Syngene International Ltd.**, said, *"We are delighted to expand Syngene's operations in Genome Valley with the addition of a large new research and development facility which will create additional jobs and contribute to the growth of the biotech industry. As a part*

*of our commitment to drive innovation and strengthen the biotech ecosystem of the country, we will be investing up to INR 788 crores over the next few years, in Genome Valley in Hyderabad. I extend my congratulations to the Government of Telangana for their visionary efforts towards setting up a world class biotech hub in Hyderabad.”*

**Jonathan Hunt, Managing Director and Chief Executive Officer of Syngene International** said, *“Scientific innovation does not happen in isolation: it is a multi-dimensional process and we have been able to make all the connections that we need at Genome Valley. Syngene started operations in here in 2020 with the inauguration of our first research laboratory. Since then, we have gradually increased our presence encouraged by the good infrastructure and availability of scientific talent, which is ideal for fast-growing organizations like Syngene. In the last 3 years, our employee base has grown to over 900 scientists. In the next expansion phase, we plan to build world-class research laboratories primarily focusing on drug discovery that will create up to another 1000 jobs.”*

## About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data management, and I.P. security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com). For the Company's latest Environmental, Social, and Governance (ESG) report, visit [Syngene-ESG21-22](#).

## Syngene's CSR outreach in Telangana

As part of Syngene's corporate social responsibility programs, in 2022, the Company funded the expansion of the mobile laboratory concept in schools by adding a 'lab on a bike,' exposing young people across government schools in Hyderabad to the world of science. The Company also funded 25 science-based scholarships for women from underserved communities, mentored by Syngene scientists based at the Hyderabad campus, providing first-hand exposure to careers in science. Over time, this program aims to increase the number of women studying STEM subjects and create a self-sustaining network of women professionals in STEM.

Media Contact	
Shotorupa Ghosh / Vijay Jeevanandham M: +91 8450977080/ +917760759922 Fax: +91 80 2852 3423 E: <a href="mailto:Shotorupa.ghosh@syngeneintl.com">Shotorupa.ghosh@syngeneintl.com</a> E: <a href="mailto:Vijay.jeevanandham@syngeneintl.com">Vijay.jeevanandham@syngeneintl.com</a>	Debalina Bhaumik M: +91 8420838919 E: <a href="mailto:debalina.bhaumik@adfactorspr.com">debalina.bhaumik@adfactorspr.com</a>